What It Is
Lentinan is a pharmaceutical-grade beta-glucan polysaccharide isolated from shiitake mushrooms (Lentinula edodes), characterized by a unique triple-helix structure composed of (1→3)-beta-D-glucan linkages with (1→6)-beta-glucopyranose branching. Its molecular weight is approximately 500,000 Daltons—a critical factor, since molecular weight determines immunological activity in the complement cascade. Lentinan was first approved in Japan in 1985 as a biological response modifier for gastric cancer adjunctive therapy. It is administered intravenously in pharmaceutical settings (1-2mg weekly doses), which is fundamentally different from oral shiitake supplements marketed for immunity. This distinction—pharmaceutical lentinan versus dietary supplement—is essential to understanding the evidence base and real-world application.
Key Structural Properties
Lentinan’s therapeutic potential derives from its specific molecular architecture. The compound consists of a regularly branched main chain of beta-(1→3)-linked glucose units with two beta-(1→6)-D-glucopyranoside branch points for every five linear beta-(1→3)-glucopyranoside linkages. This branching pattern is not random; it is conserved across shiitake cultivation and is responsible for C3 complement activation. Molecular weight preservation is critical during extraction: crude shiitake extracts and dietary supplements often contain degraded beta-glucans with reduced MW (50,000-200,000 Da), which exhibit significantly lower immunological activity than pharmaceutical-grade lentinan. This explains why oral shiitake supplements fail to replicate the survival benefits seen in Japanese clinical trials of intravenous lentinan. Oral bioavailability of intact ~500kDa lentinan is extremely limited due to the polysaccharide’s size and water solubility constraints; intestinal enzymes fragment the polymer before absorption.
How It Works
Lentinan functions as an immunological bridge rather than a direct cytotoxic agent. The triple-helix structure is recognized by pattern recognition receptors on immune cells, particularly complement component C3. Upon binding, lentinan triggers the alternative complement cascade, leading to membrane attack complex formation and direct lysis of tumor cells, as well as opsonization that enhances antibody-dependent cellular cytotoxicity. Beyond complement activation, lentinan directly enhances T-helper cell (Th1) proliferation, increasing interleukin-12 production and shifting the immune response toward cellular immunity rather than humoral immunity. Macrophage activation is another crucial mechanism: lentinan-bound macrophages upregulate MHC-II expression and antigen presentation efficiency, effectively “training” T cells to recognize and target tumor antigens more effectively. When combined with chemotherapy agents like 5-fluorouracil, lentinan appears to reduce immunosuppression that typically follows cytotoxic treatment, maintaining anti-tumor immunity when the patient would otherwise enter an immunosuppressed window.
What Research Shows
Cancer Adjunct Therapy [Strong Evidence]: Lentinan’s evidence base in gastric cancer is the strongest, stemming from Japan’s regulatory pathway. Taguchi et al. conducted a landmark Phase III randomized controlled trial (1979-1980) comparing 5-FU + mitomycin C with or without IV lentinan in advanced gastric cancer. Results showed lentinan-treated patients achieved 12.97% two-year survival (P < 0.05) versus chemotherapy alone. A subsequent meta-analysis of multiple gastric cancer trials found lentinan significantly prolonged overall survival with hazard ratio 0.80 (95% CI: 0.68-0.95). Japanese physicians have used IV lentinan as standard-of-care adjunctive therapy for gastric, colorectal, and liver cancers since the 1980s. Evidence for other cancers (prostate, breast) is weaker and based on smaller trial populations.
Immune Enhancement [Moderate Evidence]: Natural killer (NK) cell activity and T-lymphocyte proliferation are documented to increase in response to IV lentinan administration. These are robust immunological endpoints but do not directly translate to disease prevention in humans without cancer. Several small studies suggest oral shiitake supplements may modestly enhance immune markers (interferon-gamma, lymphocyte counts), but these oral formulations are not the same compound studied in cancer trials.
Oral Bioavailability Challenge [Critical Caveat]: No human trials exist demonstrating that oral shiitake supplements or oral lentinan replicate the survival benefits of IV pharmaceutical lentinan. Animal models show that oral intact lentinan is poorly absorbed; the polymer is degraded by gastric and intestinal enzymes into fragments that may retain some immunoactivity but at a fraction of pharmaceutical potency. This is not a limitation of shiitake mushrooms themselves, but rather a limitation of the delivery route and molecular form.
Dosage
Intravenous (Pharmaceutical): 1-2 mg lentinan administered weekly as an IV injection, typically as part of a cancer treatment protocol overseen by an oncologist. This is available in Japan and some Asian medical centers; it is not FDA-approved in the United States and cannot be purchased over-the-counter.
Oral Supplements (Shiitake Extract): Typical supplement dosing is 1-3 grams of shiitake extract powder or 500-1500 mg encapsulated extract daily. However, these oral forms have not been tested in human cancer trials, and their bioavailability and immunological potency remain largely unknown. Marketing claims equating oral shiitake supplements to IV lentinan should be viewed with skepticism.
Quality Markers
Distinguishing pharmaceutical-grade from supplement-grade lentinan is difficult for consumers, as most supplement labels do not specify molecular weight or provide proof of (1→3)(1→6)-beta-glucan identity. Key quality indicators include: (1) Beta-glucan content percentage (pharmaceutical lentinan is >95% pure polysaccharide; many supplements are 10-30%); (2) Molecular weight specification (should be listed as 400,000-600,000 Da for pharmaceutical-grade); (3) Third-party testing via HPLC or mass spectrometry confirming structural identity; (4) Shiitake source (whole-fruiting-body extract vs. mycelium on grain, which often contains lower beta-glucan concentrations); (5) Extraction method (water extraction for polysaccharides is standard; alcohol extraction may degrade the polymer). Supplements claiming “lentinan” without MW specification are likely lower-MW beta-glucan fragments or generic shiitake extract.
Synergies
With 5-FU Chemotherapy: The strongest synergistic evidence. Lentinan appears to preserve immune function during 5-FU-induced immunosuppression, and the combination consistently outperforms chemotherapy alone in Japanese trials.
With Other Mushroom Beta-Glucans: Reishi (beta-glucans), maitake (MD-Fraction, which is a 1,3/1,6-beta-glucan), and other medicinal mushroom polysaccharides likely activate overlapping immune pathways. Combining multiple beta-glucans may provide redundant immune stimulation, though no human trials compare these combinations directly.
With Vitamin C: In vitro data suggest vitamin C may enhance the cytotoxic effects of lentinan on tumor cells via oxidative stress. However, this has not been tested clinically.
Safety
Intravenous Administration: Mild adverse effects are reported in 2-5% of patients receiving IV lentinan, typically mild fever and chills during infusion. Serious adverse events are rare. Immune hyperstimulation is theoretically possible in patients with autoimmune conditions, though Japanese clinical experience does not document this as a major concern.
Oral Shiitake Supplements: Very safe. Gastrointestinal side effects (bloating, loose stools) are rare and mild. Shiitake is a food, and the mushroom has been consumed for centuries in Asian cuisine. No major drug interactions are documented, though beta-glucans may theoretically enhance immune responses in immunocompromised patients (not necessarily harmful, but requires medical oversight).
The Bottom Line
Lentinan—the pharmaceutical-grade, high-molecular-weight beta-glucan from shiitake—has legitimate clinical evidence as an adjunctive therapy for gastric and some other cancers when delivered intravenously. This evidence comes from Japan, where lentinan has been standard-of-care since 1985. Oral shiitake supplements may provide modest immune support based on limited data, but they are not the same compound as pharmaceutical lentinan and do not have cancer survival evidence. The molecular weight, purity, and route of administration matter enormously. If exploring lentinan for cancer adjunctive therapy, it requires discussion with an oncologist and access to IV pharmaceutical-grade material. For general immune support via oral supplements, shiitake beta-glucans are safe but should not be marketed as cancer-preventive without acknowledging the evidence-delivery gap.
This profile is educational and does not replace medical advice. Lentinan is not FDA-approved in the United States for any indication. Cancer patients considering lentinan should discuss its use with their oncology team. Oral shiitake supplements are food products and are not regulated as drugs. The information presented reflects current evidence as of July 2026; new research may modify these conclusions.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before starting any new supplement or health program, especially if you have existing medical conditions or take prescription medications.
Leave a Reply